semaglutide tirzepatide compound FDA sets compounding deadlines as shortage ends Standard Dose vs Microdose GLP-1:

Ive said this before, but it bares repeating: there is no clinical data showing that sublingual or intranasal versions of GLP-1 meds achieve therapeutic plasma levels

GLP-1 receptor agonists and DPP4-inhibitor direct the T2DM therapies

These effects are similar to what people experience on semaglutide or tirzepatide, but potentially stronger and sustained at higher doses

However, the modest effect does not negate the potential value of these drugs, especially for conditions where few effective treatment options exist, for example, dementia, Al-Aly said

GLP-1 receptor agonists work by stimulating neuroendocrine hormones which helps regulate blood sugar levels and promotes weight loss